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Abstract
Background: Hormones impact on cognition, emotions, and behaviour. Given that mental
disorders are defined by abnormalities in these very same domains, clinical psychologists may
benefit from learning more about alterations in endocrine systems, how they can contribute to
symptoms commonly experienced by patients, and how such knowledge may be put to use in
clinical practice.
Method: The aim of the present scientific update was to provide a brief overview of endocrine
research relevant to the aetiology, diagnostics, and treatment of mental disorders, including some
of the latest studies in this area.
Results: Hormones appear to be intrinsic to the development and maintenance of mental
disorders. Oxytocin is involved in social cognition and behaviour and as such may be relevant to
mental disorders characterised by social deficits (e.g., autism spectrum disorder and schizophrenia).
Stress and sex steroids exert demonstrable effects on mood and cognition. In patients with
depression and anxiety disorders, initial attempts to lower/enhance such hormones have thus been
undertaken within conventional therapies in order to improve outcomes. Finally, hunger and
satiety hormones may be involved in the vicious circle of dysfunctional eating behaviours and
weight loss/gain in anorexia or bulimia nervosa.
Conclusion: Three conclusions can be drawn from this review: First, endocrine research should be
considered when patients and clinicians are developing multidimensional illness models together.
Second, endocrine markers can complement conventional assessments to provide a more
comprehensive account of a patient’s current state. Third, endocrine testing may guide treatment
choices and inform the development of novel treatments.
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Highlights
• Hormones are intrinsic to the development and maintenance of mental
disorders
• Endocrine research should be incorporated into multidimensional illness
models
• Endocrine markers can complement conventional diagnostic assessments
• Endocrine testing may guide treatment choices and inform the development of
new treatments
Psychoneuroendocrinology is an interdisciplinary research area dedicated to the interac‐
tion between the mind, brain, and hormonal system (Wolf & Saucier, 2013). Stress and
lifestyle behaviours (e.g., diet, physical activity) are the most frequently studied psycho‐
logical factors exerting short- and long-term effects on hormones. Conversely, a number
of hormones are known to impact on psychological domains, such as cognition, emotions,
and behaviour. Among these are hormones involved in social interaction (e.g., oxytocin),
stress hormones (e.g., noradrenaline and cortisol), sex hormones (e.g., testosterone, oes‐
tradiol, and progesterone), and hormones involved in hunger and satiety (e.g., ghrelin,
leptin, or insulin). Given that mental disorders are characterised by abnormalities in cog‐
nition, emotions, and behaviour, clinical psychologists may benefit from learning more
about alterations in endocrine systems, how they may contribute to symptoms common‐
ly experienced by patients, and how such knowledge may be put to use in clinical prac‐
tice.
The aim of the present scientific update was therefore to provide a brief overview of
endocrine research relevant to the aetiology, diagnostics, and psychopharmacological and
psychotherapeutic treatment of mental disorders, including some of the latest studies in
this area. Findings will be presented separately for each of the aforementioned domains
and summarised in the final part of the manuscript alongside recommendations for clini‐
cal applications.
How Hormones Affect Social Interaction
The most prominent hormone regulating social interaction is oxytocin (Meyer-
Lindenberg, Domes, Kirsch, & Heinrichs, 2011). Although oxytocin is available in the pe‐
riphery (e.g., in reproductive organs), its central origin is in the hypothalamus, and oxy‐
tocin receptors are widely expressed in numerous areas of the brain, including the frontal
cortex, amygdala, and olfactory nucleus.
Oxytocin has demonstrable effects on social cognition and behaviour, such as enhanc‐
ing theory of mind, emotional recognition, empathy, social exploration, and attachment
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(see also Ditzen et al., 2009; Heinrichs, Baumgartner, Kirschbaum, & Ehlert, 2003). As
such, it has attracted the interest of researchers studying mental disorders characterised
by social deficits, including autism spectrum disorders and schizophrenia. There is now
evidence to suggest that oxytocin may be an aetiological factor in autism spectrum disor‐
der, since several polymorphisms within the gene encoding its receptor (OXTR) have
been found to be risk-inducing (Kranz et al., 2016; LoParo & Waldman, 2015). On the oth‐
er hand, peripheral levels of oxytocin are often found to be unaltered in the same patients
as well as in patients with psychotic disorders (Rutigliano et al., 2016). These null-find‐
ings need to be interpreted with caution, however, since the bioavailability of oxytocin in
blood, urine, or saliva does not necessarily reflect its centrally circulating levels (Valstad
et al., 2017), which are of greater importance considering the clinical features of these ill‐
nesses. Importantly, central levels are only quantifiable in humans via access to the cere‐
brospinal fluid by means of lumbar puncture. Thus, although it is unlikely that oxytocin
levels will be used as a diagnostic illness marker in the near future, their potential role in
the pathophysiology of disorders characterised by social deficits can be incorporated into
psychoeducation delivered to patients and their next of kin.
Another line of research has examined the effects of intranasally administered oxyto‐
cin in patients with autism spectrum disorder and schizophrenia (Keech, Crowe, &
Hocking, 2018), with findings of small but significant improvements in theory of mind
(but not in emotion recognition or empathy). In other words, patients receiving exoge‐
nous oxytocin showed an increased ability to attribute mental states to others, thus pro‐
viding ex juvantibus evidence for an involvement of the oxytocin system in the patho‐
physiology of these disorders. Importantly, numerous open questions need to be an‐
swered before oxytocin can be considered as an adjunct treatment for autism spectrum
disorder or schizophrenia, including its precise mechanisms of action in the brain, its
long-term efficacy, and potential adverse effects (e.g., increased irritability).
Interestingly, more recent research has explored the role of endogenous oxytocin as a
modulator of treatment outcomes. A pilot study was able to demonstrate that the lower
depressed patients’ pre-treatment oxytocin levels, the lower their degree of change in a
self-report measure of depression over the course of psychological therapy (Jobst et al.,
2018). This finding aligns well with another study in patients with depressive disorders,
which showed that oxytocin levels fluctuated during therapy sessions, and in parallel
with subtle changes in the therapeutic alliance (i.e., ruptures; Zilcha-Mano, Porat, Dolev,
& Shamay-Tsoory, 2018). Together, these studies suggest that oxytocin levels may also be
a useful prognostic tool as well as a means to monitor treatment progress.
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How Hormones Affect Cognition, Mood, and
Sexual Function
Up to now, the largest share of clinical neuroendocrine research has been dedicated to
the stress hormones noradrenaline and cortisol. The catecholamine noradrenaline (NA) is
available in the brain and in several other body tissues (Fischer & Nater, 2015). Its central
origin is the locus coeruleus, with α- and β-adrenergic receptors expressed in numerous
other brain areas, such as the cortex, thalamus, hippocampus, amygdala, and hypothala‐
mus. In the periphery, NA, together with adrenaline, is the main end product of the sym‐
pathetic nervous system, and its receptors are present in all major organs and cells of the
immune system.
Noradrenaline has effects on multiple domains of psychological functioning, includ‐
ing cognition, affect, arousal, and pain perception. It is thus unsurprising that 1) cogni‐
tive symptoms (e.g., deficits in working memory), as experienced, for instance, by pa‐
tients with depressive disorders (Maletic, Eramo, Gwin, Offord, & Duffy, 2017), 2) anxiety
and hyperarousal, representing key clinical features of panic disorder and post-traumatic
stress disorder (Bandelow et al., 2017), and 3) bodily symptoms such as fatigue and pain,
which feature prominently in somatic symptom disorders (Nater, Fischer, & Ehlert, 2011),
are all paralleled by altered NA functioning. Notably, findings are highly complex; de‐
pending on the tissue (i.e., different areas within the brain, blood), both elevated and
attenuated concentrations of NA are observed, sometimes within the same patient co‐
hort.
Drugs targeting the NA system (e.g., venlafaxine) constitute effective antidepressants
and anxiolytics (e.g., Bandelow et al., 2014; DGPPN et al., 2015), thus adding further evi‐
dence to the assumption that the NA system is instrumental in the pathophysiology of
depressive and anxiety disorders. Clinicians administering such drugs are advised to ex‐
plain the role of NA to patients before initiating treatment. By contrast, in somatic symp‐
tom disorders and in physical diseases, it is mainly the peripheral actions of NA (e.g., its
effects on the musculoskeletal or cardiovascular system) which are critical. Interestingly,
in patients undergoing coronary artery bypass graft surgery, it was recently shown that
preoperative psychological interventions led to significantly lower (i.e., more adaptive)
levels of adrenaline after surgery when compared to standard medical care (Salzmann et
al., 2017). This finding highlights the value of catecholamines as markers of therapeutic
efficacy. Notably, NA activity can also be determined non-invasively, namely via salivary
alpha-amylase, an enzyme involved in the digestion of starch, thus facilitating its use in
clinical practice (Nater & Rohleder, 2009).
The glucocorticoid cortisol, the other major stress hormone, is the end point of the
hypothalamic-pituitary-adrenal (HPA) axis (Ehlert, 2011). Although cortisol is synthe‐
sised in the adrenal cortex, both central (e.g., the hippocampus) and peripheral tissues
(e.g., lymphocytes) are densely populated by mineralocorticoid and glucocorticoid recep‐
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tors. Apart from the gluconeogenetic and anti-inflammatory effects of cortisol, one of its
main effects lies in influencing cognition.
Akin to the findings on NA, cortisol concentrations have been found to be abnormal
in a number of patients presenting with cognitive problems (e.g., difficulty concentrat‐
ing), as is the case in affective disorders (Belvederi Murri et al., 2016; Stetler & Miller,
2011). Moreover, abnormal cortisol concentrations have been demonstrated in patients
with post-traumatic stress disorder, where they may contribute to re-experiencing of
trauma via constant retrieval of the fear memory (Morris, Compas, & Garber, 2012), and
in somatic symptom disorders, where they may contribute to bodily complaints (Tak et
al., 2011). Interestingly, while patients with affective disorders are characterised by com‐
parably elevated levels of cortisol (i.e., hypercortisolism), patients with posttraumatic
stress disorder or somatic symptom disorders mostly exhibit diminished levels (i.e., hy‐
pocortisolism; Ehlert, Gaab, & Heinrichs, 2001; Heim, Ehlert, & Hellhammer, 2000). These
differences may be attributable to different genetic predispositions and/or different
amounts of stress experienced during the lifespan (Ehlert, 2013). Together, these findings
underline the potential of cortisol for improving differential diagnostics.
These findings have been extended by clinical studies, where a similar dichotomy ap‐
pears to prevail. In depression, the current state of research suggests that the higher a pa‐
tient’s pre-treatment cortisol levels, the lower their chances of responding to psychologi‐
cal therapy (Fischer, Strawbridge, Herane Vives, & Cleare, 2017). In addition, initial at‐
tempts to improve memory performance in these patients have been undertaken using
agents which act on glucocorticoid receptors (e.g., mifepristone) or influence cortisol
synthesis (e.g., ketoconazole; Soria et al., 2018). In anxiety disorders, the pattern seems to
be reversed, insofar as lower cortisol levels predict worse treatment outcomes (Fischer &
Cleare, 2017), although importantly, this only appears to be true for stimulated cortisol as
measured during exposure sessions. This has been interpreted as an implication that a
certain amount of cortisol is a prerequisite for patients to form an extinction memory,
which is one of the key mechanisms underlying successful treatment for fear-related ill‐
nesses. More recent research suggests that this knowledge may be utilised to optimise ex‐
posure-based psychological therapy for anxiety disorders. For instance, Meuret et al.
(2016) were able to demonstrate that early-day exposure sessions (i.e., when endogenous
cortisol levels are highest) led to greater clinical improvement in patients with panic dis‐
order and agoraphobia when compared to sessions held later on during the day.
Sex hormones, such as testosterone, oestradiol, and progesterone, are end products of
the hypothalamic-pituitary-gonadal (HPG) axis (Melcangi, Giatti, & Garcia-Segura, 2016).
They are mainly produced in the testes in men and in the ovaries in women, and their
key function is to orchestrate reproduction and sexual functioning. However, sex steroids
also act as neurosteroids (e.g., fostering neurogenesis and differentiation) in various parts
of the brain, such as the hippocampus and prefrontal cortex.
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In terms of mental disorders, the bulk of research to date has studied the role of sex
steroids in sexual dysfunctions. Testosterone, for instance, is lowered in men with erec‐
tile disorder (Isidori et al., 2014), and hormonal (replacement) therapy has been proven to
be useful in enhancing erectile function in hypogonadal men (Corona et al., 2017; Elliott
et al., 2017) and sexual function in post-menopausal women (Elraiyah et al., 2014). How‐
ever, long-term follow-up studies are scarce and potential adverse effects of exogenous
testosterone (e.g., acne) need to be carefully weighed against the benefits. Similarly, oes‐
trogens and combined oestrogen/progestogen treatments appear to enhance sexual func‐
tion in some post-menopausal women (Nastri et al., 2013), but again, side effects need to
be considered. These findings are important for any clinical psychologist advising pa‐
tients with sexual dysfunctions in terms of adjunct treatments.
A burgeoning literature also demonstrates the involvement of sex hormones in other
mental disorders, which is attributable to the aforementioned central expression of ste‐
roid receptors. In schizophrenia, it was shown that oestradiol and selective oestradiol re‐
ceptor modulators (e.g., raloxifene) can enhance memory and executive functions (Soria
et al., 2018). In addition, recent research suggests that sex steroids may exert positive ef‐
fects on mood. For instance, longer lifetime exposure to endogenous and exogenous oes‐
tradiol was found to be linked to fewer depressive symptoms during the menopausal
transition (Marsh et al., 2017), whereas greater fluctuations in endogenous oestradiol
during the menopausal transition predicted more depressive symptoms in women report‐
ing high amounts of stress (Gordon, Rubinow, Eisenlohr-Moul, Leserman, & Girdler,
2016). These findings not only contribute to a more profound understanding of the symp‐
toms pertaining to psychotic and mood disorders, but may ultimately be put to use in or‐
der to guide (sex-oriented) treatment choices.
How Hormones Affect Hunger and Satiety
A number of hormones regulating hunger and satiety, such as ghrelin, leptin, or insulin,
have been related to different mental disorders (Drobnjak & Ehlert, 2011). Whereas the
orexigenic hormone ghrelin is produced in the stomach, the anorexic hormones leptin
and insulin are produced in adipose tissue and in the pancreas, respectively. All three
hormones are capable of crossing the blood-brain barrier and thus directly influence en‐
ergy homoeostasis by acting on the hypothalamus.
Ghrelin, leptin, and insulin have, for the most part, been objects of research into eat‐
ing disorders. For instance, enhanced baseline ghrelin levels were reported in patients
with eating disorders (Prince, Brooks, Stahl, & Treasure, 2009), likely as a consequence of
restrained eating. Importantly, elevated levels of ghrelin may in turn facilitate other dys‐
functional behaviours, such as hoarding food in anorexia nervosa or binge eating in buli‐
mia nervosa or binge eating disorder. Furthermore, patients with anorexia nervosa have
been found to present with increased insulin sensitivity, whereas patients with bulimia
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nervosa or binge eating disorder exhibit decreased insulin sensitivity (Ilyas et al., 2018).
Similar to ghrelin, these findings have been interpreted as being the result of dietary re‐
striction and weight loss/weight gain, respectively, while at the same time further contri‐
buting to dysfunctional eating patterns by affecting appetite regulation in the brain (i.e.,
diminishing/enhancing appetite). This is important knowledge when trying to make
sense of the vicious circles that perpetuate eating disorders.
Evidence is now also accumulating that hunger and satiety hormones are abnormal in
other mental disorders, mainly those presenting with metabolic symptoms and/or comor‐
bid metabolic diseases (e.g., diabetes mellitus). Findings include elevated levels of leptin
and insulin resistance in patients with psychotic disorders (Greenhalgh et al., 2017;
Pillinger et al., 2017; Stubbs, Wang, Vancampfort, & Miller, 2016) and depressive disorders
(Kan et al., 2013). Notably, these seem to be independent of BMI and intake of antipsy‐
chotic medication (which are known to have several metabolic side effects). This suggests
that these hormonal abnormalities are not a mere consequence of lifestyle behaviours as‐
sociated with suffering from a chronic illness, but may be antecedents of highly debilitat‐
ing ancillary symptoms pertaining to psychotic and depressive disorders.
Importantly, recent studies support the notion that endogenous ghrelin and leptin
may also influence treatment outcomes: Whereas increases in ghrelin predicted non-re‐
sponses to treatment with lithium-augmented antidepressants in patients with depres‐
sion (Ricken et al., 2017), leptin was positively linked to increases in BMI (Ricken et al.,
2016). In terms of ghrelin, the observed increases in non-responders could be interpreted
as being secondary to reduced appetite, a core symptom of severe depression. In terms of
leptin, synergistic actions with lithium on the serotonergic system could have resulted in
an attenuation of leptin’s anorexic effect, but more research is warranted to investigate
the intricate interplay between the two systems. These findings are important to consider
by clinicians prescribing psychoactive drugs, and will hopefully allow the adjusting of
treatments to the needs of the individual patient in the future.
Summary and Integration
It is evident from this brief overview that hormones are intrinsic to both the development
and maintenance of mental disorders, and there are several conceivable ways in which
this knowledge may be useful to clinical psychology. First, neuroendocrine research
should find its way into clinical practice when clinicians and patients are developing
multidimensional illness models together, such as at the beginning of psychological ther‐
apy. This is important given that mental disorders are still stigmatised by a large propor‐
tion of the general population due to lay concepts about their origins (e.g., depressive dis‐
orders being seen as a lack of willpower). Second, endocrine markers may be used to aid
the (differential) diagnostics of mental disorders. This is important in light of the fact that
not all aspects of mental health are accessible by means of introspection, let alone by in‐
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dividuals who suffer from deficits in detecting and reporting signs of psychological dis‐
tress (e.g., those scoring high on alexithymia). Similarly, hormones may be used to assess
treatment outcomes above and beyond self-report symptom measures or clinical rating
scales. These ideas align well with the US National Institute of Mental Health (NIMH) Re‐
search Domain Criteria (RDoC), which aim to provide more precise characterisations of a
patient by integrating biological and psychological research (e.g., Insel et al., 2010). To
this end, a matrix combining five psychological domains (social processes, arousal/regu‐
lation, negative valence, positive valence, and cognition) with different units of analysis
(genes, molecules, cells, neural circuits, physiology, behaviour, self-reported information,
and paradigms) has been proposed. This allows for a particular state of mental illness to
be described by deficits in different psychological domains, which map on to specific bio‐
logical substrates (e.g., neuroendocrine abnormalities). Third, the results of neuroendo‐
crine testing may guide treatment choices, that is, they may support clinicians in finding
out what is likely to work for whom and why. This resonates well with the central tenet
of precision psychiatry, which advocates the tailoring of treatments to the needs of the
individual patient by integrating data from multiple levels of information (e.g., biological,
personality, and behavioural measures). On a related note, alternative or additional treat‐
ments for mental disorders may be developed that are based on a more in-depth account
of patients’ pathophysiology (e.g., hormonal substitution as an augmentation to psycho‐
logical therapy).
In the foreseeable future, clinical psychology is likely to benefit from a number of
emerging trends in psychoneuroendocrinological research. Elucidating the genetic and
epigenetic underpinnings of endocrine functioning will be crucial to fully comprehend its
role in mental disorders. As both the distribution and sensitivity of endocrine receptors
are governed by genetic variation as well as by the individual’s epigenetic make-up (e.g.,
DNA methylation), this could ultimately enable the identification of patients who run the
risk of developing mental illnesses. Similarly, learning more about the cross-talk between
different endocrine systems and between endocrine and other bodily systems (e.g., cen‐
tral monoaminergic systems) should allow for a more accurate description of how, pre‐
cisely, endocrine disturbances contribute to the onset of mental disorders – and provide
more precise targets for additional or alternative treatment options. Finally, the advent of
novel methodologies to assess hormones in a reliable, non-invasive manner (e.g., finger‐
nail cortisol) holds the promise to translate neuroendocrine knowledge into clinical prac‐
tice – and hopefully to the benefit of patients and clinical psychologists alike.
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